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Abstract-Activity of the flavin-containing monooxygenase (FMO) was reduced significantly in ascorbic 
acid deficient guinea pigs. Reduction in oxidation of dimethylaniline (DMA) and of thiobenzamide was 
associated with a decrease in the activity of the FMO. In both ascorbate supplemented and deficient 
guinea pig hepatic 12,000g supernatant fractions, SKF-525A and n-octylamine did not inhibit DMA N- 
oxidation. Phenobarbital pretreatment did not increase the rate of N-oxidation of DMA. In addition, 
hepatic supernatant fractions thermally treated at 50” were unable to N-oxidize DMA, but 80% of the 
cytochrome P-450 activity was retained. Also, N-oxidation of DMA was reduced by 53% at pH 7.0, 
while oxidation of cytochrome P-450 specific substrates was inhibited by only 19%. Kinetic studies of 
DMA N-oxidation indicate no significant change in the apparent rC;, in ascorbate supplemented or 
deficient animals. The in vitro addition of ascorbic acid had no effect on the activity of the FMO. The 
toxicological implications of the reduction in FM0 activity in ascorbic acid deficiency are discussed. 
The flavin-containing monooxygenase (FMO; EC 
1.14.13.8) catalyzes the oxidation of a large variety 
of nitrogen- and sulfur-containing drugs and environ- 
mental chemicals (l-41. For the majority of com- 
pounds, oxidation leads to less toxic derivatives but, 
depending on the functional group and substituents 
near the functional group, oxidation may also result 
in the formation of reactive intermediates which 
could lead to toxicological events [S, 61, In addition, 
cysteamine is a physiological substrate which is con- 
verted to cystamine by the FMO, suggesting a role 
for this electron transport system in generating 
disulfide bonds during protein synthesis [7], The 
FM0 has been localized in the microsomal mem- 
brane and the nuclear envelope [S, 91. The enzyme 
is present in most mammalian species, the highest 
quantity in the liver, though it is also present in the 
kidney and lungs [lo]. 
The cytochrome P-450 electron transport system 
also oxidizes amine and sulfur compounds [ 111. The 
quantities of the major components of the cyto- 
chrome P-450 system are reduced markedly in ascor- 
bic acid deficiency, from 50% for cytochrome P-450 
to 85% for cytochrome P-450 reductase [l&13]. This 
results in a significant decrease in drug oxidative 
reactions such as aniline hydroxylation, aminopyrine 
N-demethylation, p-nitroanisole 0-demethylation 
114,151 as well as steroid hydroxylation 1161. 
There is an overlap among substrates for the FM0 
and cytochrome P-450 system. The FM0 catalyzes 
oxidation of only the nitrogen and sulfur moieties of 
xenobiotics, whereas the cytochrome P-450 system 
can also oxidize the carbon substituent [17]. The 
* This work was supported in part, by Grant 23007 from 
Hoffmann-La Roche, Inc., Nutley, NJ. 
i Correspondence should be addressed to: Dr. Vincent 
G. Zannoni, Department of Pharmacology-MSl, Uni- 
versity of Michigan Medical School, Ann Arbor, MI 48109. 
metabolic products of the substrates will depend on 
the relative amounts of these two enzymes and the 
affinity of the compound for each system. 
The present study examines the effect of ascorbic 
acid deficiency on the oxidation of dimethylaniline 
(DMA) and thiobenzamide by the FMO. The effect 
of ascorbic acid deficiency on the FM0 was dif- 
ferentiated from the cytochrome P-450 system by a 
variety of physical-chemical measures. 
MATERIALS AND METHODS 
~ufe~~~~~. Sodium ascorbate, NADPH, NADH, 
and NADP+ were purchased from the Sigma Chemi- 
cal Co. (St. Louis, MO). Dimethylaniline and for- 
maldehyde were purchased from the Fisher Scientific 
Co. (Fair Lawn, NJ). Aniline, thiobenzamide and 
n-octylamine were purchased from the Aldrich 
Chemical Co. (Milwaukee, WI). Aminopyrine was 
purchased from K & K Laboratories, Inc. (Plain- 
view, NY). Dithionite and ferricyanide were pur- 
chased from the J. T. Baker Chemical Co. (Phil- 
lipsburg, NJ). p-Nitroanisole, ~-nitrophenol and p- 
aminophenol were purchased from Eastman Kodak 
(Rochester, NY). Ascorbic acid deficient diet 
(guinea pig pelleted) was obtained from Nutritional 
Biochemicals (Cleveland, OH). Male Hartley guinea 
pigs were purchased from the Michigan Department 
of Public Health (Lansing, MI). All chemicals used 
were of reagent grade or better. 
Guineapigs. Male Hartley guinea pigs (200-300 g) 
were pair fed on an ascorbic acid deficient diet for 
16-19 days; one group received 1 mg/ml of ascorbic 
acid in their drinking water daily and the. other group 
received no ascorbic acid in their drinking water. 
When the animals were killed, the average body 
weight of the ascorbic acid deficient group was 
342 2 41 g and 382 2 48 g for the ascorbic acid sup- 
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plemented group. Guinea pigs on the ascorbic acid 
deficient regimen had minimal joint hemorrhages, 
were not frankly scorbutic, and there were no sig- 
nificant differences in their rate of weight gain during 
the experimental period, compared with animals on 
the supplemented diet. Phe~obarbit~-seated guinea 
pigs were injected with 50mg/kg phenobarbital in 
saline i.p. once a day for 4 days prior to being killed. 
preparation of guinea pig tissues. Animals were 
decapitated and exsanguinated, and their livers were 
quickly removed and placed on ice. All of the fol- 
iowing procedures were carried out at 4”. Homo- 
genates (20%, w/v) were prepared in 0.25 M sucrose 
and 50 mM sodium phosphate buffer, pH 7.4, with 
a Potter-Elvehjem glass homogenizer. The homo- 
genates were centrifuged at ~OOOg for 15 min. The 
12,000 g fraction was prepared by centrifugation for 
30 min. To harvest microsomes the 12,000 g super- 
natant fraction was centrifuged for 60 min at 
100,~~~. The microsomes were made four times 
concentrated based on the initial supernatant 
volume. The 12,OOOg supernatant fraction and 
100,000 g microsomal pellet were stored at -20’; the 
activity remained stable for at least 1 year. Homo- 
genates (20%, w/v) of lungs and kidneys were pre- 
pared as described above. The whole homogenates 
were stored at -20” for no more than 15 days. The 
12,OOOg supernatant fraction was prepared on the 
day of use according to the procedure given above. 
Ascorbic acid andprotein determinations. Ascorbic 
acid concentration was determined by the method of 
Zannoni et al. [18]. Protein was determined by the 
method of Lowry et al. f193, with bovine serum 
albumin as the standard. 
~~rnet~y~un~iine ~-~x~dati~~. Dimethylaniiine N- 
oxidation was determined by the method of Ziegler 
and Pettit [8]. Incubations were carried out at 37” 
in a Dubnoff metabolic shaker using capped 25-ml 
Erlenmeyer flasks. Standard assay conditions 
included 25 mM sodium phosphate and 0.1 M glycine 
buffer, pH 8.4, 3 mM ~-octylamine, 0.5 mM 
NADPH, 2 mM dimethylaniline and 9 mg of 12,000 g 
hepatic supernatant protein, The reaction was initi- 
ated with the addition of substrate. Aliquots were 
withdraw at 3-min intervals; the reaction was ter- 
minated with 0.9 M trichloroacetic acid giving a final 
concentration of 0.3 M. Aliquots were removed, 
made basic, and extracted three times with peroxide 
free ether; the aqueous phase was acidified with 
trichloroacetic acid followed by sodium nitrate to 
develop the chromagen. A molar extinction coef- 
ficient of 8.2 mM-* cm-’ at 420 nm was used. 
Dimethylaniline N-demethylation. Dimethylani- 
line N-demethy~ation was determined at 37” by fol- 
lowing the formation of formaldehyde using the 
method of Nash [20]. The standard assay conditions 
included 0.1 M sodium phosphate buffer, pH 7.4, 
0.5 mM NADPH, 2mM DMA and 2.5mg of 
lOO,~O~ microsomal protein. A molar extinction 
coefficient of 6.9 mM_’ cm-” at 412 nm was used. 
Thio~e~zum~de ~-~x~dutio~, Thiobenzamide S- 
oxidation was measured as described by Cashman 
and Hanzlik [21]. Incubations were monitored at 
370 nm in a Cary 219 dual beam spectrophotometer 
at 37”. Standard assay conditions included 25 mM 
sodium phosphate, 0.1 M glycine buffer, pHg.3, 
1.5 mM n-octylamine, an NADPH-generating sys- 
tem and 3 mg of 12,OOOg hepatic supernatant 
protein; the final volume was 1 ml. The NADPH- 
generating system consisted of 0.25 mM NADP”, 
5 mM MgC12, 5 mM glucose&-phosphate and 
0.2 units/ml glucose-6-phosphate dehydrogenase. 
The reactions were initiated by the ad~tion of 5 ~1 
of thiobenzamide, l.OmM, in acetonitrile to the 
sample cuvette and 5 $ of acetonitrile to the ref- 
erence cuvette. Thiobenzamide S-oxide had a molar 
extinction coefficient of 2930 M-’ cm-’ at 370 nm. 
Cytochrome P-450. Cytochrome P-450 was deter- 
mined in 12,000 g hepatic supernatant fractions from 
the reduced carbon monoxide difference spectrum 
according to the method of Gmura and Sato [22]. 
The standard assay conditions included 0. I ml (1 mg) 
sodium dithionite solution added only to the exper- 
imental cuvette (stock solution, 30mg of sodium 
dithionite plus 15 mg of sodium bicarbonate in 3.0 ml 
of H&J), 9 mg of 12,~~ hepatic supernatant 
protein, 0.1 m&M EDTA and 0.05 M sodium phos- 
phate buffer, pH 7.4, in a total volume of 1 ml [23]. 
A molar extinction coefficient of 91 rnM_l cm-’ was 
used. 
Cytochrome bs. The quantity of microsomal cyto- 
chrome b, was determined from the NADH dif- 
ference spectrum according to the method of Umura 
and Sato [22]. The standard assay conditions 
included 0.4 mM NADN, 3.2 mg of 100,000 g micro- 
somal protein, 0.1 mM EDTA and 0.05 M sodium 
phosphate buffer, pH 7.4. A molar extinction coef- 
ficient of 185 mM-r cm--’ was used. 
NADH cytuchrome b5 reductase. Microsomal 
NADH cytochrome bs reductase activity was deter- 
mined as described by Muhara and Sato [24f. The 
standard assay conditions included 0.1 mM NADH, 
1 mM potassium ferricyanide, 0.024 mg of lOO,O~g 
microsomal protein and 0.1 M potassium phosphate 
buffer, QH 7.5, at 27”. A molar extinction coefficient 
of 1.02 mM-i cm-’ at 420 nm was used. 
p-~~tr~unis~~e ~-demethy~utio~. p-Nitroanisole G- 
demethylation in hepatic 12,000 g supernatant frac- 
tion was determined spectrophotometrically at 
415 nm using the modified method of Zannoni [25]. 
The reaction was started by the addition of 1.7 mM 
p-nitroanisole to 0.25 mM NADPH, 9 mg of 12,000 g 
super~atant protein, and 0.1 M sodium phosphate 
buffer, pH 7.4, at 37”. A molar extinction coefficient 
for ~n~trophenol of 11.4mM-r cm-r was used at 
pH7.4 and 16mM-i cm-‘” for assays conducted 
above the pH of 8.4. 
Arn~~opyr~ne N-demethyl~tion. Aminopyrine N- 
demethylation was determined at 37” by following 
the formation of formaldehyde by the method of 
Nash [ZO]. The standard assay conditions included 
2mM aminopyrine, OSmM NADPH, 3mg of 
100,OOOg microsomal protein and 0.1 M sodium 
phosphate buffer, pH 7.4. A molar extinction coef- 
ficient of 6.9 mM_’ cm-i at 412 nm was used. 
Aniline hydroxylation. Aniline hydroxylation was 
determined by measuring the quantity of p-amino- 
phenol formed which, when complexed with phenol, 
absorbs light at 640nm 1261. The standard assay 
conditions included 1.6 mM aniline, il.5 mM 
NADPH, 6 mg of 12,000 g hepatic supernatant frac- 
tion protein and 0.1 M sodium phosphate buffer, 
Ascorbic acid and the Aavin-containing monooxygenase 



















1.20 2 0.60 (20) 9.3 + 3.4 (20) 25.0 2 5.6 (7) 0.97 t 0.18 (7) 
0.66 of: 0.30* (20) 4.7 2 1.6* (20) 22.0 k 4.6 (7) 1.0 t 0.15 (7) 
Assays were carried out as described under Materials and Methods. Dimethylaniline and cytochrome P- 
450 were assayed in the 12,000 g supernatant fraction and cytochrome b5 and cytochrome bS reductase were 
assayed in the l~,~g microsomal pellet. The average hepatic level of ascorbic acid in supplemented 
animals was 29 t 13 mg/lOO g wet liver weight and 1.8 + 1.3 mg in the deficient animals. The numbers in 
parentheses equal the number of animals, and the data are means k SD. 
* P < 0.001. 
pH7.4, at 37”. A molar extinction coefficient of 
25 mM_’ cm-’ was used. 
Statistical analysis. Data were subjected to stat- 
istical analysis using a two-sided Student’s t-test. 
RESULTS 
As can be observed in Table 1, guinea pigs main- 
tained on an ascorbic acid free diet exhibited a sig- 
nificant decrease (45%) in the hepatic N-oxidation 
of dimethylaniline, a relatively specific substrate for 
the flavin-containing monooxygenase [I, 171. As pre- 
viously established, the specific quantity of cyto- 
chrome P-450 was found to be reduced on the order 
of 50%. In contrast, the specific quantity of cyto- 
chrome bS, another heme protein, and the specific 
activity of cytochrome b5 reductase were found to 
be unaffected by ascorbic acid deficiency. 
The N-oxidation of DMA was stimulated more 
than 2-fold by 3 mM a-octylamine in both normal 
and ascorbic acid deficient hepatic supernatant prep- 
arations (Fig. 1A). In contrast, the oxidation of 
aniline, a cytochrome P-450 substrate, was inhibited 
at least 90% (Fig. IS). In addition, 1 mM SKF-525A, 
another cytochrome P-450 system inhibitor, 
inhibitedp-nitroanisole (p-NA) oxidation by at least 
60%) but did not affect significantly the N-oxidation 
of DMA. 
The effect of 3 mM n-octylamine on the oxidation 
of aminopyrine, aniline and dimethyIaniline in hep- 
atic microsomes was also determined (data not 
shown). In keeping with the resuts found with the 
hepatic 12,000 g supernatant fractions, the presence 
of n-octylamine inhibited the oxidation of amino- 
pyrine and aniline by at least 90%. The metabolism 
of DMA to the N-oxide, via the FMO, was stimulated 
1.5 to 3-fold while the formation of formaldehyde, 
via carbon oxidation by cytochrome P-450, was 
inhibited by 65%. 
Phenobarbital pretreatment of guinea pigs 
increased the specific quantity of cytochrome P-450 
and enhanced hydroxylation of aniline in both ascor- 
bate supplemented and deficient animals, whereas 
N-oxidation of DMA was not enhanced in the pres- 
ence or absence of n-octylamine (Table 2). In fact, 
in ascorbate supplemented animals the specific 
activity of DMA N-oxidation was reduced by pheno- 
barbital pretreatment to the level in the deficient 
p-NA p-NA aniline aniline 
Fig. 1. Effect of cytochrome P-450-MFO inhibitors. Assays were carried out as described in Materials 
and Methods. Activity equals nmoles product/min/mg 12,000g hepatic supernatant fraction. For DMA 
the N-oxide product was determined. p-Nitroanisole equals p-NA. The average hepatic level of ascorbic 
acid in supplemented animals was 29 k 13 mg/lOO g wet liver and 1.8 t 1.3 mg in the deficient animals. 
The data presented in the figure represent a typical experiment. Key: (a) plus ascorbate diet; (0) no 
ascorbate diet; (5) SKF-S25A, 1 mM; and (a) n-octylamine, 3 mM. 
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Table 2. Effect of phenobarbital on the P-450-MFO and FM0 
Dimethylaniline 
Cytochrome P-450 Aniline (nmoles N-oxide/min/mg protein) 
Treatment (nmoles/lOO mg protein) (nmoles/min/mg protein) +n-Octylamine -n-Octylamine 
Deficient diet 
plus ascorbate 
No phenobarbital 9.3 ” 3.4 (20) 0.048 ‘-c 0.013 (7) 1.20 t 0.60 (20) 0.66 t 0.17 (4) 
With phenobarbital 15.8 2 3.2 (9) 0.109 r 0.031 (9) 0.67 r 0.24 (9) 0.34 + 0.06 (4) 
Deficient diet 
No phenobarbital 4.7 t 1.6 (20) 0.026 2 0.009 (7) 0.66 t 0.30 (20) 0.27 c 0.10 (4) 
With phenobarbital 9.8 t 1.4 (8) 0.056 f 0.017 (8) 0.66 If: 0.17 (8) 0.32 + 0.06 (4) 
Assays were carried out as described under Materials and Methods in 12,000g hepatic supernatant fraction. The 
average hepatic level of ascorbic acid in supplemented animals was 29 t 13 mg/lOO g wet liver weight and 1.8 i 1.3 mg 
in the deficient animals. The numbers in parentheses equal the number of animals, and the data are means k SD. 
Table 3. Hepatic thiobenzamide S-oxidation 
Activity (nmole product/min/mg protein) 









1.13 zt 0.42 (6) 0.55 rt 0.17 (6) 
0.58 + 0.36* (6) 0.28 rt O.lO* (6) 
0.80 + 0.14 (6) 0.74 c 0.09 (6) 
0.74 i: 0.24 (6) 0.54 t 0.15 (6) 
Assays were carried out at 37” as described under Materials and Methods 
in 12,000 g hepatic supernatant fraction. The average hepatic level of ascorbic 
acid in supplemented animals was 29 2 13mg/i~g wet liver weight and 
1.8 IT 1.3 mg in the deficient animals. The numbers in parentheses equal the 
number of animals, and the data are means C SD. 
* P < 0.05. 












10.4 -c 2.8 (3) 0.048 2 0.009 (3) 1.41 -c 0.79 (3) 




5.4 2 1.7 (3) 0.026 k 0.009 (3) 0.46 C 0.10 (3) 
4.7 + 0.8 (3) 0.022 i 0.004 (3) ND* 
Assays were carried out in hepatic 12,000 g supernatant fraction as described under Materials 
and Methods. Both the thermally treated and untreated supernatant fractions contained 0.2 mM 
butylated hydroxytoluene which stabilizes the cytochrome P-450 system during thermal treatment 
1271. The supernatant fraction was heated to 50” for 3.5 min. The average hepatic level of ascorbic 
acid in supplemented animals was 29 i 13 mg/lOO g wet liver weight and 1.8 +- 1.3 mg in the 
deficient animals. The numbers in parentheses equal the number of animals, and the data are 
means k S.D. 
* Non-detectable: limit of assay equals <0.02 nmole/min/mg protein. 
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Table 5. pH-Activity profiles 
Cytochrome P-450 system 
7.0 9.4 
641 
p-Nitroanisole (nmoles/min/mg protein) 
Deficient diet 
plus ascorbate 
0.26 * 0.09 (3) 0.32 +. 0.13 (3) 0.14 ” 0.09 (3) 
Deficient diet 0.10 e 0.02 (3) 0.11 ir 0.03 (3) 0.05 c 0.01 (3) 
FM0 system 
PH 
7.0 8.4 9.4 
Dimethylaniline (nmoles N-oxide/min/mg protein) 
Deficient diet 
plus ascorbate 
0.38 5 0.13 (3) 0.81 I?z 0.18 (3) 0.66 t 0.07 (3) 
Deficient diet 0.21 2 0.02 (3) 0.45 2 0.18 (3) 0.37 r 0.25 (3) 
Assays were carried out as described under Materials and Methods in hepatic 
12,000 g supernatant fraction. The incubation was carried out in 0.1 M sodium 
phosphate buffer at pH 7.0 and 0.2 M Tris buffer at pH 9.4. The average hepatic 
level of ascorbic acid in supplemented animals was 29 t 13 mg/lOO g wet liver 
weight and 1.8 2 1.3 mg in the deficient animals. The numbers in parentheses 
equal the number of animals, and the data are means t S.D. 
guinea pigs. The enhancement of DMA N-oxidation, 
found with n-octylamine, was maintained in both the 
ascorbate supplemented and deficient phenobar- 
bital-induced guinea pigs. 
The effect of ascorbic acid deficiency as well as 
phenobarbital pretreatment on the metabolism of 
another FM0 substrate, thiobenzamide, was deter- 
mined in the presence and absence of 1SmM n- 
octylamine (Table 3). Consistent with the decrease 
found in the N-oxidation of DMA, the S-oxidation 
of this substrate was reduced by 47% in the ascorbic 
acid deficient guinea pigs; in addition, there was a 2- 
fold stimulation in the presence of n-octylamine. In 
the ascorbic acid supplemented phenobarbital 
induced guinea pigs, the S-oxidation of thio- 
benzamide in the presence of n-octylamine 
approached the level of the deficient animals. This 
is similar to the findings with DMA N-oxidation 
(Table 2). In contrast to DMA N-oxidation, the 
activation by n-octylamine was not observed in the 
phenobarbital induced animals. 
The specific quantity of cytochrome P-450 and the 
oxidation of aniline were reduced by, at most, 18% 
(which is not statistically significant) when normal 
and ascorbic acid deficient hepatic 12,000g super- 
natant fractions were thermally treated at 50” for 
3.5 min (Table 4). This is in marked contrast to the 
effect on DMA N-oxidation, which was inhibited 
over 95% after thermal treatment. 
The pH-activity profiles for the cytochrome P-450 
substrate, ~-nitroanisole, and the FM0 substrate, 
DMA, were measured in 12,000g hepatic super- 
Table 6. Hepatic compartmental distribution of DMA N-oxidation and cytochrome P-450 
Fraction 
Dimethylaniline Cytochrome P-450 
(nmoles N-oxide/min/mg protein) (nmoles/lOO mg protein) 
Deficient diet Deficient % Deficient diet Deficient % 
plus ascorbate diet Decrease plus ascorbate diet Decrease 
Whole homogenate 1.8 0.65 64 
1,000 g Pellet 2.5 0.88 65 17 17 0 
12,000 g Supernatant 1.4 0.41 70 14 7 51 
12,000 g Pellet 4.0 2.8 30 39 30 23 
Microsomal pellet 9.8 3.2 67 75 35 53 
Assays were carried out as described under Materials and Methods. Pellets prior to use were washed with the initial 
volume of buffer (0.25 M sucrose and 50 mM sodium phosphate, pH 7.4), homogenized, and centrifuged at the appropriate 
speed. The supernatant fraction was decanted, and the pellet was brought up to the original volume. The average hepatic 
level of ascorbic acid in supplemented animals was 29 C 13 mg/lOO g wet liver weight and 1.8 2 1.3 mg in the deficient 
animals. The quantity of cytochrome P-450 cannot be determined in the whole homogenate. The data presented in the 
figure represent a typical experiment. 
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Table 7. DMA N-oxidation in extrahepatic tissues 
Activity (nmoies N-oxide/min/mg 
protein) 
Deficient diet 
Fraction plus ascorbate Deficient diet 
Lung 
Whole homogenate 1.05 c 0.22 (3) 0.96 ” 0.21 (3) 
12,000 g Supernatant 0.43 -+ 0.19 (3) 0.39 2 0.09 (3) 
Kidney 
Whole homogenate 0.35 2 0.06 (3) 0.33 f 0.06 (3) 
12,000 g Supe~natant 0.21 ” 0.07 (3) 0.16 t 0.03 (3) 
Assays were carried out at 37” as described under Materials and 
Methods. The average hepatic level of ascorbic acid in sup- 
plemented animals was 29 2 13 mg/lOOg wet liver and 
1.8 t 1.3 mg in the deficient animals. The numbers in parentheses 
equal the number of animals, and the data are means t S.D. 
natant fractions (Table 5). At pH 9.4 the oxidation 
ofp-nitroanisole was decreased by .56%, whereas the 
N-oxidation of DMA was decreased by only 18% 
when compared to their optimal pH activity at pH 
7.4 and 8.4 respectiveiy. This is in contrast to the 
effect at pH 7.0, where the oxidation of p-nitro- 
anisoie was decreased by 19% while DMA N-oxi- 
dation was reduced by 53%. The effect of pH was 
consistent whether the supernatant fraction was iso- 
lated from ascorbate supplemented or deficient 
guinea pigs. 
The decrease in hepatic DMA N-oxidation found 
in the ascorbic acid deficient guinea pig 12,000g 
supernatant fractions was maintained in the whole 
homogenate, the 1OOOg pellet, the 12,000g pellet, 
Fig. 2. Lineweaver-Burk ptot of DMA N-oxidation. Each 
data point was determined individually with 12,OOOg hep- 
atic supernatant fraction, 3 mM n-octylamine, 0.1 M 
glycine, 25 mM sodium phosphate buffer, pH 8.4, incu- 
bated at 37” for 25 and 50min. The quantity of DMA 
present is indicated in the figure. The average hepatic level 
of ascorbic acid in supplemented animals was 29 + 13 mg/ 
100 g wet liver and 1.8 2 1.3 mg in the deficient animals. 
The data presented in the figure represent the mean of four 
individual experiments. Key: (A) plus ascotbate diet; and 
(x) no ascorbate diet. 
and the microsomal pellet (Table 6). In contrast to 
the decrease in N-oxidation of DMA in the 1OOOg 
pellet, the specific quantity of cytochrome P-450 was 
not affected. 
The N-oxidation of DMA in the kidney and lung 
was not affected significantly by ascorbic acid deiici- 
ency (Table 7). The specific activity of DMA N- 
oxidation in ascorbate supplemented guinea pig lung 
12,000 g supernatant fraction was 36% of the hepatic 
activity, while the deficient guinea pig lung super- 
natant fraction was 60% of the hepatic activity 
(Table 1). 
The apparent Michaelis-Menten affinity constant 
(K,) for DMA N-oxidation was 8.2 x 10e4 vs 
7.4 X 1W4 M at pH 8.2 in the hepatic 12,000 g super- 
natant fraction of the ascorbate supplemented and 
deficient guinea pigs respectively (Fig. 2). Fur- 
thermore, ascorbic acid (1 or 5 mM) added, in uitro, 
had no effect on the oxidation of DMA or thio- 
benzamide. In addition, when 12,OOOg hepatic 
supernatant fractions from ascorbate supplemented 
and ascorbic acid deficient guinea pigs were 
combined, the resulting specific activity of DMA N- 
oxidation was additive. 
DISCUSSION 
The participation of ascorbic acid in drug metab- 
olism is relatively selective, in that it affects specific 
enzyme systems, and is not a general membrane 
effect. The N-oxidation of dimethyIaniline (DMA), 
a substrate of the flavin-monooxygenase (FMO), is 
reduced signi~cantly in ascorbic acid deficiency. The 
cytochrome P-450 monooxygenase electron trans- 
port system is also jeopardized, but only the quantity 
of three specific hepatic microsomal cytochrome P- 
450 polypeptide hemoproteins are decreased [28] m In 
addition, the present study indicates that the specific 
quantity of cytochrome bg, another membrane heme 
protein, and the specific activity of cytochrome b5 
reductase were not affected by ascorbic acid defici- 
ency (Table I). 
The abserved decrease in oxidation by the FM0 
in ascorbic acid deficiency was differentiated from 
Ascorbic acid and the flavin-containing monooxygenase 643 
the decrease in the cytochrome P-450 system by the 
use of specific inhibitors, phenobarbital pretreat- 
ment, thermal treatment, and pH-activity profiles. 
SKF-525A, a potent inhibitor of the cytochrome P- 
450 system, did not significantly affect the N-oxi- 
dation of DMA. n-Octylamine, another inhibitor of 
the cytochrome P-450 system increased the rate of 
N-oxidation of DMA. In keeping with this, n-octyl- 
amine has been reported previously to activate the 
FM0 in hog, hamster and guinea pig [29]. It acts, 
presumably, at a regulatory site distinct from the 
catalytic site 1301. The decrease in DMA N-oxidation 
found in ascorbic acid deficiency was maintained in 
the presence of either SKF-525A or n-octylamine. 
Phenobarbital pretreatment did not induce DMA 
N-oxidation and, in fact, DMA N-oxidation in the 
ascorbic acid supplemented guinea pigs was reduced 
to the level of the deficient animals. On the other 
hand, the cytochrome P-450 system was induced 
on the order of 2-fold in both the ascorbic acid 
supplemented and deficient guinea pigs. Pheno- 
barbital pretreatment has been shown previously to 
reduce significantly the specific content of the hepatic 
FMO, and this effect has been explained as due, in 
part, to an increase in the quantity of other non- 
FM0 endoplasmic reticulum proteins such as cyto- 
chrome P-450 [la]. However, since the reduction 
in specific activity occurred only in the ascorbate 
supplemented guinea pigs, and the induction of cyto- 
chrome P-450 occurred in both the ascorbate sup- 
plemented and deficient animals, it is difficult to 
attribute the effect of phenobarbital to this. 
Since the FM0 is highly sensitive to thermal inac- 
tivation [27], it was possible to selectively denature 
the FM0 without inactivating cytochrome P-450. N- 
oxidation of DMA was not detected after thermal 
treatment of both ascorbic acid supplemented and 
deficient hepatic preparations. In contrast, the 
specific quantity of cytochrome P-450 was unaffected 
and the oxidation of cytochrome P-450 substrates 
was reduced by less than 20%. The reduction in N- 
oxidation of DMA in ascorbate deficiency via the 
FM0 was further clarified by using pH-activity pro- 
files. The N-oxidation of DMA was reduced by 53% 
at pH 7.0 in both ascorbate supplemented and 
deficient preparations, while the rate of oxidation of 
cytochrome P-450 substrates was not significantly 
affected at this pH. 
The sulfoxidation of thiobenzamide, another sub- 
strate for the FMO, was also reduced in ascorbic 
acid deficiency. However, compared to the N-oxi- 
dation of DMA, it was a less specific substrate in 
that it is S-oxidized also by the cytochrome P-450 
system [31]. In ascorbate supplemented pheno- 
barbital-pretreated guinea pigs, as was found with 
the N-oxidation of DMA, the oxidation of thio- 
benzamide in the presence of ~-octyl~ine was 
reduced to the level of the deficient animals. The 
activation of metabolism by n-octylamine, however, 
was not found with thiobenzamide in the pheno- 
barbital-treated guinea pigs. This may be due to the 
induction of the cytochrome P-450 system which 
contributes to the oxidation of this substrate in the 
absence of n-octylamine. 
Compartmental distribution of the N-oxidation of 
DMA indicated that it was diminished in the hepatic 
1OOOg pellet isolated from the ascorbate deficient 
guinea pigs, whereas the quantity of cytochrome P- 
450 was unaffected (Table 6). This would result in 
an imbalance in the relative amounts of cytochrome 
P-450 and FM0 in the deficient animals, with poss- 
ibly toxicological consequences. For example, the in 
uiuo administration of corticosteroids or vitamin E 
depletion causes an increase in N-oxygenation of 
aromatic amines accompanied by a decrease in their 
N-demethylation, via cytochrome P-450, which 
results in an enhanced tumor-inducing capacity of 
the amines [32]. In addition, Chiele and Malvaldi [6] 
have demonstrated that in viva liver necrosis which 
results from the metabolism of thioacetamide is 
inhibited by preadministration of methimazole, an 
inhibitor of the FMO. Furthermore, an alteration in 
the liver to lung FM0 activity ratio occurs in ascorbic 
acid deficiency (Tables 1 and 7). This alteration may 
enhance the susceptibility of deficient guinea pigs to 
pulmonary toxic compounds that are metabolized by 
the FMO, such as a-naphthylthiourea [33]. The fact 
that ascorbic acid does not affect FM0 in lung and 
kidney may reflect differences in the structures of 
the enzyme in these two tissues. In keeping with this, 
Williams et al. 1341 have purified rabbit lung FM0 
and found it to be immunochemically and cata- 
lytically distinct from the liver enzyme. 
Our investigation of the effect of ascorbic acid on 
FM0 indicates that there is no significant difference 
in the apparent Michaelis-Menten affinity constant 
for DMA N-oxidation. Furthermore, the addition of 
ascorbic acid in vitro had no effect on the oxidation 
of DMA or thiobenzamide. Also, when hepatic 
supernatant fractions from ascorbic acid 
supplemented guinea pigs are combined with 
deficient guinea pig fractions, the resultant N-oxi- 
dation of DMA is additive. It has been suggested 
that the FM0 enzyme exists as aggregates of several 
monomeric units and that the active enzyme is an 
octamer which is in equilibrium with tetrameric 
forms [l, 351. One possible explanation for the 
decrease in FM0 activity found in ascorbic acid 
deficiency is that an alteration occurs in the equi- 
librium between monomeric forms, which could lead 
to decreased FM0 activity. Another is that the FM0 
can be controlled by levels of steroids 1361, and it 
is known that ascorbic acid deficiency leads to an 
alteration in steroid metabolism [Xi]. However, the 
exact biochemical mechanism and toxicological 
consequence of the reduction in FM0 activity in 
ascorbic acid deficiency are heretofore unknown. 
REFERENCES 
1. D. M. Ziegler, in Enzymatic Basis of Detoxication (Ed. 
W. B. Jakoby), Vol. 1. p. 201. Academic Press, New 
York (1980). 
2. R. A. Prough, P. C. Freeman and R. N. Hines, J. bid. 
Chem. 256, 4178 (1981). 
3, L. L. Paulsen, Re;. b&hem. Toxic. 3, 33 (1981). 
4. N. P. Haiiar and E. Hodrson. Science 209.1134 (1980). 
5. R. A. &ough, Archs kochem. Biophys. lSb, 442 
(1973). 
6. E. Chiele and G. Malvaldi, Toxicology 31, 41 (1984). 
7. D. M. Ziegler and L. L. Poulsen, Trends biochem. Sci. 
2, 79 (1977). 
644 J. I. BRODFUEHRER andV. G. ZANNONI 
8. D. M. Ziegler and F. H. Pettit, Biochem. biophys. Rex. 
Commun. 15, 185 (1964). 
9. S. E, Pattoa, G. M. Rosen, E. J. Rauckman, D. G. 
Grahm, B. Small and D. M. Ziegler, &%kc. Pharmac. 
18. 151 (1980). 
IO. G. A. Dannan and F. P. Guengerich, Motet. Pharmac. 
22,787 (1982). 
11. J. R, Gillette, B. B. Brodie and B. N. La Du, J. 
Pharmac. exp. Titer. 119, 532 (1957). 
12. V. Cr. Zannoni, E. J. Flynn and M. M, Lynch, B&hem. 
Pharmac. 21, 1377 (1972), 
13. E. Degkwitz, S. Walsh, M. Dubberstein and J. Winter. 
Ann. N.Y. Acad. Sa. 258, 201 (1975). 
14. V. G. Zannoni and M. M. Lynch, Drug Metab. Rev. 
2, 57 (1973). 
15. E. Degkwitz, S. Walsch and M, Dubberstein, Hype- 
Seyleer’s 2. physiol. Chem. 355, 11.52 (1974). 
16. E. Ginter, Ann. N.Y. Acad. Sci. 258, 410 (1975). 
17. R. A. Prougb and D. M. Ziegler, Archs E&hem. 
Biophys. 180, 363 (1977). 
18. V. G. Zannoni, M. M. Lynch, S. Goldstein and P. I-I. 
&to, Biochem. Med. 11,41 (1974). 
19. 0. H. Lowry, N. J. Rosebrough, A. L. Farr and R. J. 
Randall, J. bi&. Ckm. 193, 26.5 (1951). 
20. T. Nash, Biochem. J. 55,416 (1953). 
21. J. R. Cashman and R. P. Ha&k, Biochem. biophys. 
Res, Commun. 98, 147 (1981). 















S. S. Lau, G. D. Abrams and V. G, Zannoni. J. 
Pharmac. exp. Ther. 214, 703 (1980). 
K. Mihara and R. Sate, Mesh. Ensym. 52, 102 (1978). 
V, G. Zannoni, F~~~~~e~~~~ of Drug Me&bal~m and 
ofDrug L?tiposich (Eds. B. W. La Du, H. G. Mandel 
and E. L. Way), p. 556. Williams& Wilkins. Baltimore 
(1971). 
R. Kato and I. R. Gillette, J. Pharmac. exp. T/ter. 150, 
279 (1965). 
L. L. Paulsen, R. M. Hyslop and D. M. Ziegler, Archs 
&o&em. Biaphys. 198,78 (1979). 
L. E. Rikans, C. R. Smith and V. G. Zannoni, 1. 
Pharmnc. ewp. Tiler. 204, 7U2 (1978). 
L. L. Paulsen, R. M. Hyslop and D. M. Ziegler, 
Biu&em. Phrrrmar. 23, 3431 (1974). 
M. C. Dyroff and R. A. Neal, Molec. Pharmac. 23, 
219 (1983). 
R, E. Tynes and E. Hodgson. Bicxfrem. Pharmac. 32, 
3419 (1983). 
E. Arrhenius, Cartcer Rev. 28, 264 (1968). 
R. A. Neal, Reu. &&em. Tnxic. 2, 131 (1980). 
D. E. Williams, D. M. Ziegler, D. J. Nordin, S. E. 
Hale and 3. S. S. Masters, Biuchem. bto$~ys. Res. 
&onmun, 125, 116 (1984). 
N. B. Beaty and D, P. Ballou, 1. biol, Chem. 256;,4611 
(1981). 
M. W. Duffel, J. M. Graham and D. M. Ziegler, M&c. 
PhavYKYc. 19, 134 (1981). 
